Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Zanubrutinib in B-cell Malignancies
NCT04170283Phase 3Active, not recruiting
- Sponsor
- BeOne Medicines
- Start
- Jan 2020
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 18
01
Overview
A Phase 3 trial of zanubrutinib in B cell malignancies, sponsored by BeOne Medicines. Started Jan 2020; status: active, not recruiting.
02
Drugs
zanubrutinib
03
Conditions
B cell malignancies
Beyond the preview
Go deeper on NCT04170283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04170283.